BSP Pharmaceuticals S.r.l. was glad to announce that its new manufacturing Sterile Department - Sterile 3 - was successfully audited by AIFA (Italian Medicine Agency), during its last General GMP Inspection of 12 - 18 December 2013.
The Sterile 3 suite was projected to be a unique manufacturing system specially designed for anticancer drugs, with the flexibility to manage small molecules and the complexity of ADC products.
Sterile 3 suite capabilities:
LYO SURFACE: 2x323 sqf
VIAL SIZES range from 2 ml to 100 ml
CLOSED RABS (cRABS) to have the highest level of sterility assurance and containment